ArticleFrontiers in medicine2026
Association of sleep quality and inner-ear-specific biomarkers Otolin-1 and otoconin-90 with disease severity in benign paroxysmal positional vertigo.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Benign paroxysmal positional vertigo (BPPV) is the most common peripheral vestibular disorder and exhibits marked heterogeneity in symptom burden and clinical course. Objective biomarkers reflecting inner-ear structural status and their relationship with clinical manifestations remain limited. Emerging evidence suggests an association between sleep quality and vertigo symptoms; however, the biological basis underlying this relationship is poorly understood. Methods: In this case-control study, 268 patients with BPPV and 268 age- and sex-matched healthy controls were enrolled. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), and vertigo severity was evaluated using the Dizziness Handicap Inventory (DHI). Serum levels of the inner-ear-specific structural biomarkers Otolin-1 and otoconin-90 (OC90) were measured using enzyme-linked immunosorbent assays. Logistic regression was used to examine associations with BPPV presence. Among patients with BPPV, multivariable linear regression, joint models, and exploratory mediation analyses were conducted to evaluate relationships among sleep quality, biomarkers, and symptom severity. Results: Compared with healthy controls, patients with BPPV exhibited significantly higher serum levels of the inner-ear structural biomarkers Otolin-1 (median 6.38 vs. 3.94 ng/mL) and otoconin-90 (median 12.64 vs. 7.58 ng/mL), both of which were independently associated with the odds of BPPV (adjusted OR for Otolin-1: 2.08, 95% CI: 1.49-2.91; adjusted OR for otoconin-90: 1.71, 95% CI: 1.21-2.42). Among patients with BPPV, poorer sleep quality was associated with greater vertigo severity (β = 2.14 per PSQI point, 95% CI: 1.56-2.72). Higher PSQI scores were also associated with increased levels of Otolin-1 and otoconin-90, both of which were independently related to vertigo severity. Inclusion of these biomarkers in joint models attenuated the PSQI-DHI association (β from 2.14 to 1.28) and improved model explanatory power (R Conclusion: These findings indicate that otolith-related inner-ear structural biomarkers are associated with both the presence and severity of BPPV and may partially explain the relationship between sleep quality and vertigo symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.